Scarica l'app Stockscreener
2.27
8.28%
-0.205
Dopo l'orario di chiusura:
2.27
Sana Biotechnology Inc Borsa (SANA) Ultime notizie
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com - Investing.com Canada
Form 4 Sana Biotechnology Inc For: 11 October By Investing.com - Investing.com South Africa
Viking Therapeutics plans $400M stock and conve... - Pluang
Sana Biotechnology (Nasdaq:SANA)Stock Analysis - Simply Wall Street
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com Australia
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com Canada
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com UK
Sana Biotechnology | 8-K: Current report - Moomoo
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - The Conway Daily Sun
Sana Biotechnology to Present at September 2026 Investor Conferences - manilatimes.net
Sana Biotechnology to Present at September 2026 Investor Conferences - GlobeNewswire
Four September presentations will feature Sana Biotechnology’s business update - Stock Titan
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer PATEL DHAVALKUMAR DHIRAJLALmoomoo - Moomoo
Sana (SANA) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison; Post-Report: Shares Finish 4.55% Higher in the Latest SessionRevenue Report - vinanet.vn
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention - Kalkine Media
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - Sahm
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - simplywall.st
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2%Time to Sell? - MarketBeat
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely? - Moomoo
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9%Still a Buy? - MarketBeat
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses? - Sahm
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - theglobeandmail.com
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - MarketBeat
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - MarketBeat
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - simplywall.st
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - manilatimes.net
SANA Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Capital DisciplineEarnings Surprise Report - vinanet.vn
SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com Nigeria
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com South Africa
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com Canada
7.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):